Andrea Ferrario, Alessandro Pulsoni, Barbara Olivero, Giuseppe Rossi, Umberto Vitolo, Alessandra Tedeschi, Francesco Merli, Luigi Rigacci, Caterina Stelitano, Maria Goldaniga, Donato Mannina, Pellegrino Musto, Francesca Rossi, Enrica Gamba and Luca Baldini Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas Cancer 118
Version of Record online: 16 DEC 2011 | DOI: 10.1002/cncr.26708
Indolent nonfollicular non-Hodgkin B-cell lymphomas are clonal mature B-cell proliferations for which treatment has not been defined to date. The combination of rituximab, fludarabine, and cyclophosphamide as induction immunochemotherapy followed by a short maintenance phase with rituximab is a highly effective regimen with acceptable toxicity in this subset of lymphomas.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field